Ketofol Versus Propofol in Urgent ERCP for Acute Cholangitis
Conscious Sedation Failure During Procedure
About this trial
This is an interventional health services research trial for Conscious Sedation Failure During Procedure
Eligibility Criteria
Inclusion Criteria:
- Severe acute cholangitis of either sex
- Aged between 21-70 years
- Undergoing urgent therapeutic ERCP for severe cholangitis with American Society of Anaesthesiologist (ASA) Grade II - III.
Exclusion Criteria:
- Patients who had ASA physical status Grade VI,
- Baseline SpO2 <90%,
- Patients who had difficulty in communication,
- Patients allergic to the studied medications,
- Morbidly obese patients,
- Patients with chronic obstructive pulmonary disease,
- Complicated airway,
- Pregnant patients.
Sites / Locations
- Assiut UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Ketofol group
Propofol group
Patients undergoing urgent therapeutic ERCP for severe cholangitis, with American Society of Anaesthesiologist (ASA) Grade II - III. Will receive Ketofol (ketamine: propofol concentration 1:4) prepared in 50 ml syringe containing dextrose 5% (each ml contained 8 mg propofol and 2 mg ketamine), administered as following; 5 ml of ketofol as loading then infusion titrated till targeted RSS score.
Patients undergoing urgent therapeutic ERCP for severe cholangitis, with American Society of Anaesthesiologist (ASA) Grade II - III. Sedation was initially started by bolus dose of 0.5 mg/kg propofol IV over 3 minutes then, infusion was started at the rate of 50 µg /kg/min till RSS score of 5.